Waters Corporation (WAT) 2003 Annual Report Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2003. Waters Corporation is a leading manufacturer of analytical instruments, primarily High Performance Liquid Chromatography (HPLC), Mass Spectrometry (MS), and Thermal Analysis/Rheology systems. The company serves pharmaceutical, life science, industrial, academic, and government customers. In 2003, Waters completed the integration of its Micromass (MS) and HPLC divisions into a single Waters Division, aggregating reporting into one segment alongside the TA Instruments (TAI) division.
Key Financial Metrics
| Metric | 2003 | 2002 |
|---|---|---|
| Net Sales | $958.2 million | $890.0 million |
| Gross Profit | $560.4 million | $516.5 million |
| Gross Margin | 58.5% | 58.0% |
| Operating Income | $219.2 million | $196.4 million |
| Net Income | $170.9 million | $147.7 million |
| Diluted EPS | $1.34 | $1.09 |
| Operating Cash Flow | $157.0 million | $219.4 million |
| Cash and Equivalents | $356.8 million | $263.3 million |
| Total Debt (Current + Long-term) | $246.3 million | $7.5 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 8% to $958.2 million. Excluding favorable currency effects, sales were essentially flat. Product sales grew 4%, while service sales grew 22%.
- Segment Performance: HPLC sales grew ~5% (driven by consumables and service), and Thermal Analysis grew ~20% (including Rheometrics acquisition). MS sales declined ~18% (excluding the sold inorganic line) due to patent litigation impacts and reduced pharmaceutical capital spending.
- Profitability: Operating income rose 12% to $219.2 million, driven by higher gross profit and reduced litigation provisions ($1.5M in 2003 vs. $7.9M in 2002) and restructuring charges ($0.9M net in 2003 vs. $7.4M in 2002).
- Debt and Liquidity: The company significantly increased leverage to fund a $324.6 million stock repurchase program. Net borrowings rose to $246.3 million, primarily under a new $125 million term loan and revolving credit facility.
- Acquisitions: Waters acquired Creon Lab Control AG ($16.3M) and Rheometrics Scientific ($16.5M), resulting in a $6.0 million charge for expensed in-process R&D.
Guidance, Outlook, Risks, and Unusual Items
- Legal Settlements: In April 2003, the company paid $53.7 million in damages and interest related to the Applera patent litigation. In March 2004 (subsequent to year-end), a settlement was reached involving a one-time payment of $18.1 million (accrued at year-end) and cross-licensing agreements.
- Environmental: The company paid a $5.9 million civil penalty and agreed to a $0.6 million environmental project regarding its Taunton, MA facility.
- Restructuring: A new restructuring plan initiated in January 2004 is expected to result in a $2.0 million charge in Q1 2004, involving the termination of approximately 80 employees.
- Risks: Key risks include the high concentration of sales to the pharmaceutical industry (53% of 2003 sales), foreign currency fluctuations (55% of sales outside the U.S.), and ongoing patent litigation uncertainties.
- Capital Allocation: The company completed a $200 million buyback and authorized an additional $400 million repurchase program. No dividends are planned.
Investor Verification Checklist
- Patent Litigation Exposure: Verify the final status and financial impact of the Applera settlement and any remaining international claims.
- MS Segment Recovery: Assess whether the 18% decline in MS sales is a temporary market correction or a structural loss of market share.
- Debt Service Capacity: Review the company's ability to service the new $246.3 million debt load while maintaining R&D investment and funding the new $400 million buyback authorization.
- Acquisition Integration: Monitor the integration progress and revenue contribution of the Creon and Rheometrics acquisitions.
- Pharma Dependency: Evaluate the sensitivity of future revenue to capital spending cycles in the pharmaceutical sector.